Table 2

Summary of PRO reporting in chemotherapy-based trials with or without immunotherapy for LA-NPC

Study (identifier)Sample size*StageStudy designInterventional regimensPRO scales
Liu et al.1 (NCT03700476)357III–IVA, except T3–4N0 and T3N1 (AJCC 8th)Multicenter, phase 3, RCTGP IC + CCRT + sintilimab (induction, concurrent, and adjuvant)EORTC QLQ-C30
Liang et al.2 (NCT03427827)334T4N1M0/T1–4N2–3M0 (AJCC 8th)Multicenter, phase 3, RCTGP IC + CCRT + adjuvant camrelizumabEORTC QLQ-C30
Liu et al.3 (NCT03925090)87III–IVA (AJCC 8th)single-center, phase 2, RCTCCRT + toripalimab (induction and adjuvant)EORTC QLQ-C30, EORTC QLQ-H&N35
Xu et al.4 (NCT04907370)532T4N1M0/T1–4N2–3M0 (AJCC 8th)Multicenter, phase 3, RCTGP IC + IMRT + toripalimab (induction, concurrent, and adjuvant)PRO-CTCAE, EORTC QLQ-C30, EORTC QLQ-H&N35, FACT-G, FACT-H&N
Xu et al.5 (NCT03984357)152T4N1M0/T1–4N2–3M0 (AJCC 8th)Multicenter, phase 2, single-armGP IC + IMRT + nivolumab (induction, concurrent, and adjuvant)PRO-CTCAE, EORTC QLQ-C30, EORTC QLQ-H&N35, FACT-G, FACT-H&N
You et al.6 (NCT04453826)572T4NxM0/TxN3M0 (AJCC 8th)Multicenter, phase 3, RCTGP IC + CCRT + camrelizumab (concurrent and adjuvant)EORTC QLQ-C30
Lv et al.7 (NCT04072107)306III–IVA (AJCC 8th)Multicenter, phase 2ctEBV DNA-guided risk-adapted therapyEORTC QLQ-C30
Chen et al.16 (NCT02958111)335III–IVA, except T3–4N0 and T3N1 (AJCC 8th)Multicenter, phase 3, RCTDefinitive chemoradiotherapy + adjuvant metronomic capecitabineEORTC QLQ-C30
Tang et al.17 (NCT01540136)145T1–4N1–3M0/T3–4N0M0 (AJCC 7th)Two centers, phase 3, RCTIMRT + concurrent nedaplatinEORTC QLQ-C30, QLQ-H&N35

PRO, patient-reported outcome; LA-NPC, locoregionally advanced nasopharyngeal carcinoma; GP, gemcitabine-cisplatin; IC, induction chemotherapy; CCRT, concurrent chemoradiotherapy; IMRT, intensity-modulated radiotherapy; MRLN, medial retropharyngeal lymph node; ctEBV, circulating tumor Epstein-Barr; AJCC, American Joint Committee on Cancer; RCT, randomized controlled trial; CTCAE, Common Terminology Criteria for Adverse Events; EORTC, European Organisation for Research and Treatment of Cancer; QLQ-C30, quality-of-life questionnaire core-30; QLQ-H&N35, quality-of-life questionnaire head-and-neck-35; FACT-G, Functional Assessment of Cancer Therapy-General; FACT-H&N, Functional Assessment of Cancer Therapy-Head and Neck. *Recorded sample size is the maximum number of respondents across the different PRO questionnaires.